Cost–utility analysis of once-daily versus twice-daily inhaled corticosteroid dosing for maintenance treatment of asthma in pediatric patients

Journal of Asthma

Volumn 53, Issue 5, 2016, Pages 538-545

  Rodriguez Martinez, Carlos E ^a,b,c   Sossa Briceño, Monica P ^d   Castro Rodriguez, Jose A ^e  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b UNIVERSIDAD EL BOSQUE   (Colombia)

^c HOSPITAL MILITAR CENTRAL   (Colombia)

^d UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^e PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Adherence; asthma; cost effectiveness; inhaled corticosteroids; quality adjusted life years

Indexed keywords

CORTICOSTEROID; ANTIASTHMATIC AGENT;

ARTICLE; ASTHMA; COHORT ANALYSIS; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEALTH CARE COST; HUMAN; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); CHILD; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; ECONOMICS; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; HUMANS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84955126733     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2015.1116087     Document Type: Article

References (45)

1. L.J.Akinbami, J.E.Moorman, P.L.Garbe, E.J.Sondik. Status of childhood asthma in the United States, 1980–2007. Pediatrics 2009;123(Suppl 3):S131–S145
2. R.J.Dennis, L.Caraballo, E.García, M.X.Rojas, M.A.Rondon, A.Pérez, G.Aristizabal,. Prevalence of asthma and other allergic conditions in Colombia 2009-2010: a cross-sectional study. BMC Pulm Med 2012;12:17
3. Centers for Disease Control and Prevention. National Center for Health Statistics. CDC Wonder On-line Database, compiled from Compressed Mortality File 1999–2011 Series 20 No. 2Q, 2014
4. R.W.Morton, M.L.Everard, H.E.Elphick. Adherence in childhood asthma: the elephant in the room. Arch Dis Child 2014;99:949–953
5. R.Horne. Adherence to asthma medication: a question of ability? Prim Care Respir J 2011;20:118–119
6. A.J.Claxton, J.Cramer, C.Pierce. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296–1310
7. S.A.Eisen, D.K.Miller, R.S.Woodward, E.Spitznagel, T.R.Przybeck. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881–1884
8. L.P.Boulet, D.Vervloet, Y.Magar, J.M.Foster. Adherence: the goal to control asthma. Clin Chest Med 2012;33:405–417
9. M.Masoli, M.Weatherall, R.Beasley. Fluticasone given once versus twice a day: meta-analysis. Respirology 2005;10:183–188
10. C.E.Rodriguez-Martinez, M.P.Sossa-Briceno, J.A.Castro-Rodriguez. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma. J Asthma 2013;50:410–418
11. C.E.Rodriguez-Martinez, G.Nino, J.A.Castro-Rodriguez. Cost-utility analysis of daily versus intermittent inhaled corticosteroids in mild-persistent asthma. Pediatr Pulmonol 2015;50:735–746
12. N.Adams, T.J.Lasserson, C.J.Cates, P.W.Jones. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2007;4:Cd002310. DOI: 10.1002/14651858.CD002310.pub4
13. P.Manning, P.G.Gibson, T.J.Lasserson. Ciclesonide versus other inhaled steroids for chronic asthma in children and adults. Cochrane Database Syst Rev 2008;2:Cd007031. DOI: 10.1002/14651858.CD007031
14. H.W.Kelly. Comparison of inhaled corticosteroids: an update. Ann Pharmacother. 2009;43:519–27
15. A.Briggs, M.Sculpher. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998;13:397–409
16. M.J.Price, A.H.Briggs. Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics 2002;20:183–194
17. S.B.Barnett, T.A.Nurmagambetov. Costs of asthma in the United States: 2002–2007. J Allergy Clin Immunol 2011;127:145–152
18. E.Martinez-Moragón, J.Serra-Batllés, A.De Diego, M.Palop, P.Casan, C.Rubio-Terrés, C.Pellicer. por el Grupo de Investigadores del estudio AsmaCost. Arch Bronconeumol 2009;45:481–486
19. J.C.Dubus, J.Anhoj. A review of once-daily delivery of anti-asthmatic drugs in children. Pediatr Allergy Immunol 2003;14:4–9
20. G.Jonasson, K.H.Carlsen, C.Jonasson, P.Mowinckel. Low-dose inhaled budesonide once or twice daily for 27 months in children with mild asthma. Allergy 2000;55:740–748
21. K.E.Wells, E.L.Peterson, B.K.Ahmedani, L.K.Williams. Real-world effects of once vs greater daily inhaled corticosteroid dosing on medication adherence. Ann Allergy Asthma Immunol 2013;111:216–220
22. C.S.Rand, R.A.Wise. Measuring adherence to asthma medication regimens. Am J Respir Crit Care Med 1994;149:S69–S76
23. M.P.Celano, J.F.Linzer, A.Demi, R.Bakeman, C.O.Smith, S.Croft, L.J.Kobrynski. Treatment adherence among low-income, African American children with persistent asthma. J Asthma 2010;47:317–322
24. N.S.Jentzsch, P.Camargos, E.S.Sarinho, J.Bousquet. Adherence rate to beclomethasone dipropionate and the level of asthma control. Respir Med 2012;106:338–343
25. N.S.Jentzsch, P.A.Camargos, E.A.Colosimo, J.Bousquet. Monitoring adherence to beclomethasone in asthmatic children and adolescents through four different methods. Allergy 2009;64:1458–1462
26. K.A.McNally, J.Rohan, M.Schluchter, K.A.Riekert, P.Vavrek, A.Schmidt, S.Redline,. Adherence to combined montelukast and fluticasone treatment in economically disadvantaged african american youth with asthma. J Asthma 2009;46:921–927
27. J.Mallol, V.Aguirre. Once versus twice daily budesonide metered-dose inhaler in children with mild to moderate asthma: effect on symptoms and bronchial responsiveness. Allergolog Immunopathol 2007;35:25–31
28. A.Briggs, K.Claxton, M.Sculpher. Decision modeling for health economic evaluation. New York: Oxford University Press; 2006
29. Y.C.Shih, J.Mauskopf, R.Borker. A cost-effectiveness analysis of first-line controller therapies for persistent asthma. Pharmacoeconomics 2007;25:577–590
30. C.F.Chiou, M.R.Weaver, M.A.Bell, T.A.Lee, J.W.Krieger. Development of the multi-attribute Pediatric Asthma Health Outcome Measure (PAHOM). Int J Qual Health Care 2005;17:23–30
31. Sistema de Información de precios de medicamentos—SISMED. Listado de precios promedio y unidades en la cadena de comercialización de medicamentos. Ministerio de la Protección Social. República de Colombia. Available from: http://www.consultorsalud.com/biblioteca/documentos/2012/Precios%20reportados%20de%20medicamentos%20diciembre%202011.pdf [last accessed 15 April 2015]
32. Guıa de Práctica Clínica (GPC) para el diagnóstico, atención integral y seguimiento de niños y niñas con diagnóstico de asma. Available from: http://gpc.minsalud.gov.co/guias/Pages/Guía-de-asma-en-niños.aspx [last accessed 18 April 2015]
33. British Guideline on the Management of Asthma. A national clinical guideline. British Thoracic Society. Scottish Intercollegiate Guidelines Network. Revised edition published 2014. Available from: https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2014/ [last accessed 18 April 2015]
34. H.Linstone, M.Turoff. The Delphi method. Techniques and applications. Los Angeles, CA: University of Southern California; 2002
35. Banco de la República, Colombia. Series estadísticas. Tasas de cambio. Santa Fe de Bogota: Banco de la República; 2011. Available from: http://www.banrep.gov.co/series-estadisticas/see_ts_cam.htm [last accessed 19 April 2015]
36. B.J.O'Brien, M.F.Drummond, R.J.Labelle, A.Willan. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994;32:150–163
37. A.H.Briggs, R.Goeree, G.Blackhouse, B.J.O'Brien. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002;22:290–308
38. A.Miller-Larsson, H.Mattsson, E.Hjertberg, M.Dahlback, A.Tunek, R.Brattsand. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998;26:623–630
39. L.P.Boulet. Once-daily inhaled corticosteroids for the treatment of asthma. Curr Opin Pulm Med 2004;10:15–21
40. H.W.Kelly. Comparison of inhaled corticosteroids: an update. Ann Pharmacother 2009;43:519–527
41. P.Weiner, M.Weiner, Y.Azgad. Long term clinical comparison of single versus twice daily administration of inhaled budesonide in moderate asthma. Thorax 1995;50:1270–1273
42. A.Bush, H.J.Zar. WHO universal definition of severe asthma. Curr Opin Allergy Clin Immunol 2011;11:115–121
43. J.F.Guest, A.M.Davie, F.J.Ruiz, M.J.Greener. Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. Prim Care Respir J 2005;14:88–98
44. A.Richter, S.E.Anton, P.Koch, S.L.Dennett. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307–2335
45. B.G.Bender, C.Rand. Medication non-adherence and asthma treatment cost. Curr Opin Allergy Clin Immunol 2004;4:191–195